Search
BioCryst Pharmaceuticals Inc
BCRXAdd to Watchlist
8.330USD
+0.060+0.73%
Close 09-30 16:00（ET）
2.12BMarket Cap
LossP/E TTM
BioCryst Pharmaceuticals Inc (BCRX) Stock Price Target & Forecast
Analyst Rating
Based on 11 analysts giving stock ratings to BioCryst Pharmaceuticals Inc in the past month.
Buy
3 Strong Buy
6 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
21.500USD+150.29%
BCRX Analyst Recommendation Trends
In the current month, BCRX has received 6 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BCRX average Analyst price target in the last month is 21.500.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
3
3
3
3
6
6
7
7
7
7
6
6
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
11
10
10
10
10
9
9
BCRX Analyst Rating for Peer Comparison
Updated: Sep 30, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, BCRX EPS is projected to reach 0.082 in FY2026Q3, following reported EPS of 0.308 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.04
0.05
0.12
0.08
0.11
Actual
1.17
-2.98
0.31
--
--
Surprise
+2976.19%
-6234.49%
+159.83%
--
--
FAQs
What is BioCryst Pharmaceuticals Inc's expected revenue for the next quarter?
BioCryst Pharmaceuticals Inc's expected revenue is 165.67M.
What is BioCryst Pharmaceuticals Inc's price target?
Analysts forecast that BioCryst Pharmaceuticals Inc's price target is USD 21.50, with the highest forecast at USD 32.00 and the lowest forecast at USD 11.00.
How have BioCryst Pharmaceuticals IncBCRX's recent earnings per share performed?
The market expectation was USD 0.31, while BioCryst Pharmaceuticals IncBCRX's earnings per share (EPS) for the previous quarter was USD -2.98. EPS for the next quarter is expected at USD 0.08.
What is the analyst rating for BioCryst Pharmaceuticals Inc?
Based on the ratings of BioCryst Pharmaceuticals Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.